Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accutane Prescriptions Would Be Limited To Approved Indication Under House Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation from Reps. Stupak and Smith calls for mandatory registry for all Accutane users, prescribers and dispensers. The bill is based upon Roche's latest proposed risk management plan but adds some consumer protection provisions, such as an informed consent requirement for all patients.

You may also be interested in...



Accutane Legislation Planned; Rep. Stupak Wants Mandatory Registries

The registry would require participation of all patients, prescribers, and dispensers of isotretinoin. Stupak calls into question the ability of Roche and FDA to manage such a registry.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel